Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism (Q34278853)

1 August 2017

1 reference

title

Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism (English)

1 reference

1 August 2017

main subject

venous thromboembolism

1 reference

L M Lopez

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

21

1 reference

1 August 2017

issue

6 Pt 2

1 reference

1 August 2017

page(s)

56S-61S; discussion 71S-72S

1 reference

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low-molecular-weight heparin for the treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Thrombosis prophylaxis with low molecular weight heparin in total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.8.56S.34596

10.1592/PHCO.21.8.56S.34596

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference